A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
暂无分享,去创建一个
D. Chakrabarti | T. Powles | D. Petrylak | Y. Tomita | P. Grivas | J. Aragon-Ching | M. Shnaidman | E. Kessler | Y. Faroun | R. Laliberté